Amneal Pharmaceuticals, Inc. (AMRX) SEC Filings & Earnings Calls

Integration risk of combining two companies' operations and cultures.

“Integration planning and related activities are underway” · word for word

Execution risk in biosimilar launches and pipeline advancement.

“advancing the biosimilar pipeline” · word for word

Pharmaceutical Tariff Risk

“On May 13, 2026, the President announced the findings of a Section 232 investigation into pharmaceutical imports and the imposition of tariffs on certain FDF and API, under which certain branded pharmaceutical products and their APIs are subject to tariffs of up to 100%” · word for word

Operating Cash Flow Negative

“Net cash used in operating activities was $48.0 million for the six months ended June 30, 2026 as compared to net cash provided by operating activities of $91.2 million in the prior year period” · word for word

Legal and Litigation Exposure

“For the three months ended June 30, 2026, charges related to legal matters, net were $8.1 million, primarily consisting of charges related to antitrust class action litigation.” · word for word

Execution risk on Kashiv acquisition and integration.

“Kashiv acquisition and integration costs of approximately $30 million.” · word for word

Opioid settlement costs continue to impact cash flow.

“Opioid settlement costs of approximately $36 million.” · word for word

Pharmaceutical Tariff Exposure

“On April 2, 2026, the President announced the findings of a Section 232 investigation into pharmaceutical imports and the imposition of tariffs on certain FDF and API.” · word for word

Opioid Litigation Cash Outflow

“$35.9 million of litigation settlement payments related to the Nationwide Opioids Settlement Agreement” · word for word

Negative Operating Cash Flow

“Net cash used in operating activities was $26.7 million for the three months ended March 31, 2026” · word for word

AvKARE segment revenue declined 4% due to shift away from low-margin distribution channel.

“AvKARE net revenue declined 4% as growth in the government channel was offset by a decline in the low margin distribution channel.” · word for word

Acquisition subject to regulatory approvals and stockholder votes; may not close or may be delayed.

“subject to, among other things, the satisfaction of certain closing conditions, including ... the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act”

Significant contingent payments up to $350M and 12-year royalty obligations could impact future cash flows.

“Sellers will also be eligible to receive up to an additional $350,000,000 in potential contingent payments”

Insider selling pressure

“Between November 14, 2024 and December 31, 2025, trusts controlled by the Reporting Person sold 6,924,729 shares of Class A Common Stock in open market transactions at prices per share between $7.74 and $12.42.” · word for word

Insider selling pressure

“Between November 14, 2024 and December 31, 2025, trusts controlled by the Reporting Person sold 6,924,729 shares of Class A Common Stock in open market transactions at prices per share between $7.74 and $12.42.” · word for word

Concentrated ownership and control by Amneal Group

“As of December 31, 2025, the Amneal Group controlled approximately 48% of the voting power of all of the Company’s common stock.” · word for word

Related party transactions with Kashiv Biosciences

“Chirag Patel and Chintu Patel beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, 50% in the aggregate of the outstanding equity securities of Kashiv.” · word for word

Significant debt and interest expense

“Interest expense, net $241,091 (in thousands) for FY2025.”

Affordable Medicines segment revenue timing risk

“Affordable Medicines net revenue decreased 1% due to the timing of revenue for key products and new launches” · word for word

Debt service risk

“If our cash flows and capital resources are insufficient to fund our debt service obligations, we could face substantial liquidity problems and could be forced to reduce or delay investments and capital expenditures or to dispose of material assets or operations, seek additional debt or equity capital or restructure or refinance our indebtedness.” · word for word

Generic price erosion risk

“Generic pharmaceuticals have faced regular and increasing price erosion each year, placing even greater importance on our ability to continually introduce new products.” · word for word

Concentrated ownership risk

“As of December 31, 2025, the Amneal Group controlled approximately 48% of the voting power of all of our outstanding shares of common stock.” · word for word

Tax receivable agreement liability

“If utilization of our DTAs becomes more-likely-than-not in the future, at such time, we could incur obligations approximating the $129.1 million unrecorded contingent TRA liability as of December 31, 2025.” · word for word

Tariff risk

“Given the global nature of pharmaceutical supply chains, any changes to historically prevailing tariff requirements could impact us and our industry by increasing costs, affecting product availability, and/or disrupting supply chains.” · word for word

Increased leverage from new term loan of $134.7M, though offset by interest savings.

“The Company incurred a new term loan with an aggregate principal amount of $134,673,472.50.” · word for word

Opioids settlement liability of up to $132.9M cash and $177.4M product; multi-year payment obligation.

“Company will pay $88.5 million and provide up to $177.4 million in naloxone nasal spray”

Tariff exposure on pharmaceutical imports

“During 2025, President Trump has announced a number of tariff actions, and while there are currently no reciprocal tariffs on pharmaceutical products imported into the U.S., this can change at any moment.” · word for word

Opioid litigation settlement costs

“During July 2025, we deposited an aggregate of $24.2 million into dedicated accounts as a step in the process to finalize a definitive settlement agreement.” · word for word

Impairment charges on non-promoted products

“Specialty cost of goods sold for the three months ended September 30, 2025 increased 41.0% compared to the prior year period, primarily due to an impairment charge related to a non-promoted product of $22.1 million.” · word for word

R&D milestone payments and commercial investments pressuring near-term margins.

“increased commercial investments to support the CREXONT® and BREKIYA® autoinjector launches and a slight increase in research and development expenses, which included a $22.5 million milestone” · word for word